Several studies have revealed that the mechanism of action behind the beneficial effect of CEF in neurodegenerative diseases like PD (Leung et al., 2012; Chotibut et al., 2014, 2017; Hsu et al., 2015; Zhang et al., 2015), AD (Zumkehr et al., 2015), HD (Miller et al., 2008; Sari et al., 2010), and ALS (Yamada and Jinno, 2011) is mediated by enhancing the expression of GLT-1 mRNA levels. This evidence concerns the gene SLC1A2 and Huntington disease.